Press coverage about CASI Pharmaceuticals (NASDAQ:CASI) has trended somewhat positive on Tuesday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. CASI Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.6150276653047 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

CASI Pharmaceuticals (NASDAQ:CASI) opened at $2.51 on Tuesday. CASI Pharmaceuticals has a fifty-two week low of $0.91 and a fifty-two week high of $4.84.

CASI Pharmaceuticals (NASDAQ:CASI) last announced its earnings results on Monday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.01). research analysts anticipate that CASI Pharmaceuticals will post -0.15 earnings per share for the current fiscal year.

CASI has been the subject of several recent research reports. ValuEngine downgraded CASI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, July 22nd. Maxim Group set a $4.00 price objective on CASI Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 14th. Finally, HC Wainwright restated a “buy” rating and issued a $2.00 price objective on shares of CASI Pharmaceuticals in a report on Friday, September 8th.

TRADEMARK VIOLATION WARNING: “CASI Pharmaceuticals (CASI) Earning Somewhat Favorable Media Coverage, Study Finds” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at

In other news, Director Wei-Wu He bought 315,327 shares of CASI Pharmaceuticals stock in a transaction on Friday, September 15th. The stock was acquired at an average cost of $1.33 per share, for a total transaction of $419,384.91. Following the completion of the acquisition, the director now owns 212,323 shares of the company’s stock, valued at approximately $282,389.59. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders acquired 996,329 shares of company stock valued at $1,647,138 over the last quarter. 13.01% of the stock is currently owned by corporate insiders.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Insider Buying and Selling by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.